ArticleFrontiers in immunology2026
Predicting CAR-T outcomes in R/R DLBCL: a multicenter real-world study of a 5-index model.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The clinical management of relapsed or refractory diffuse large B‑cell lymphoma (R/R DLBCL) has been transformed by chimeric antigen receptor T‑cell therapy (CAR‑T), yet a significant challenge remains in predicting which patients will derive long‑term benefit. Methods: This multicenter retrospective real‑world study aimed to validate a previously developed efficacy prediction model for CD19 CAR‑T in Chinese patients with R/R DLBCL. A total of 92 patients with DLBCL who received CD19 CAR‑T across four Chinese centers from August 1, 2021, to November 30, 2024 were included. The 5‑index prediction model (incorporating double‑expressor lymphoma status, TP53 alterations, ECOG performance status ≥2, bulky disease ≥5 cm, and prior therapy lines ≥4) was applied to predict treatment outcomes. The primary endpoints were overall response rate (ORR), complete response (CR) rate, progression‑free survival (PFS), and overall survival (OS). Results: The median follow‑up was 14.6 months. The C‑index for the 5‑index model was 0.767, indicating good predictive performance. The model effectively stratified patients into different risk groups, with significant differences observed in PFS (P < 0.0001) and OS (P = 0.0007) across groups. The model outperformed traditional prognostic indices such as IPI and R‑IPI. Discussion: The 5‑index risk model demonstrated robust predictive ability in a real‑world setting, providing a reliable basis for personalized treatment decisions in Chinese DLBCL patients undergoing CAR‑T. Future work will focus on further optimizing the model and conducting multi‑regional validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.